GC and melanoma: Additionally, Gc-/- mice bearing 5555 BrafV600E melanoma or MCA-205 fibrosarcoma tumors displayed greater responses to anti-PD1 and anti-CTLA-4 checkpoint blockade immunotherapies than C57BL6/J wild type (WT) mice (Fig. 1D-F).